文献速递肝病消化道肿瘤与早癌

增强肝纤维化评分与肝硬度测量改善反映肝细胞癌风险降低

Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2019-04-25

研究纳入453例接受抗病毒治疗的慢性乙型肝炎患者,这些患者在2006-2013年间接受瞬时弹性成像检查且LSM-HCC评分≥11(中高风险),至少3年后重复瞬时弹性成像并检测ELF评分。平均随访56个月期间45例(9.9%)发生肝细胞癌。联合LSM-HCC与ELF评分的敏感度(86.7%)和阴性预测值(95.3%)高于任一评分单独使用。

要点

  • LSM-HCC评分≥11的慢性乙型肝炎抗病毒治疗患者中,联合ELF评分可提高HCC预测敏感度(86.7%)和阴性预测值(95.3%)。
  • LSM-HCC评分改善、不变、恶化的患者分别占71.4%、24.3%、4.3%;ELF评分改善、不变、恶化的患者分别占36.9%、57.8%、5.3%。
  • Kaplan-Meier分析显示ELF评分有助于进一步区分LSM-HCC中危患者的HCC风险(P=0.026),但对高危患者无此作用(P=0.770)。

核心结论

  • 联合LSM-HCC评分与ELF评分的两步算法可提高接受抗病毒治疗的慢性乙型肝炎患者HCC预测准确性。

研究设计与样本

  • 研究纳入2006-2013年间接受瞬时弹性成像检查、LSM-HCC评分≥11(中高风险)的慢性乙型肝炎患者,至少3年后重复瞬时弹性成像,并通过调取瞬时弹性成像检查前4周内储存的血清样本检测ELF评分,主要终点为HCC累积发生率。
  • 共纳入453例慢性乙型肝炎患者(平均年龄51.7±10.3岁;男性74.4%),平均随访56个月期间45例(9.9%)发生HCC。

主要发现

  • LSM-HCC评分改善、不变、恶化的患者分别占71.4%、24.3%、4.3%;ELF评分改善、不变、恶化的患者分别占36.9%、57.8%、5.3%。
  • 联合LSM-HCC与ELF评分的敏感度(86.7%)和阴性预测值(95.3%)高于任一评分单独使用。
  • Kaplan-Meier分析显示ELF评分有助于进一步区分LSM-HCC中危患者的HCC风险(P=0.026),但对LSM-HCC高危患者无此作用(P=0.770)。

关键数值与推荐

  • LSM-HCC评分中高风险定义为11分或以上。
  • 联合LSM-HCC与ELF评分的敏感度为86.7%,阴性预测值为95.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Liver stiffness measurement hepatocellular carcinoma (LSM-HCC) score predicts HCC accurately in patients with chronic hepatitis B (CHB). AIM: To assess the ability of LSM-HCC combined with enhanced liver fibrosis (ELF) score to predict HCC in CHB patients who received anti-viral treatment. METHODS: CHB patients who had transient elastography examinations in 2006-2013 with intermediate and high risk of HCC by LSM-HCC score (ie 11 or above) were assessed by repeat transient elastography at least 3 years later. ELF score was assessed by retrieving the stored serum samples 4 weeks within transient elastography examination. The primary endpoint was the cumulative incidence of HCC. RESULTS: A total of 453 CHB patients (mean age 51.7 ± 10.3 years; male 74.4%) were recruited, 45 patients (9.9%) developed HCC during the mean follow-up of 56 months. Regarding LSM-HCC score, 71.4%, 24.3% and 4.3% of patients had LSM-HCC score improved, remained static and deteriorated respectively; whereas 36.9%, 57.8% and 5.3% of patients had ELF score improved, remained static and deteriorated respectively. The sensitivity (86.7%) and negative predictive value (NPV) (95.3%) of combined LSM-HCC and ELF score were higher than that of each score alone. Kaplan-Meier analysis showed that ELF score would help further differentiate the HCC risk in patients with intermediate risk by LSM-HCC score (P = 0.026), but not in patients with high risk by LSM-HCC score (P = 0.770). CONCLUSIONS: The two-step algorithm combining LSM-HCC score and ELF score could improve the accuracy of predicting HCC of CHB patients receiving anti-viral treatment.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Liang LY, Wong VW, Tse YK, et al. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2019. PMID: 31025388. doi:10.1111/apt.15269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。